May 6, 2021 — Weight loss is a minor part of obesity care. It’s blindingly obvious, but most people have a tough time wrapping their heads around this basic fact. A new study in the New England Journal of Medicine today tells this story in a very elegant way. It’s all about controlling weight over time. Getting Weight Loss […]
February 11, 2021 — A new study of semaglutide in the New England Journal of Medicine is causing quite a stir in the news. (If you can get past impeachment headlines.) In fact, both experts and headline writers are calling semaglutide for obesity a game changer. Meanwhile, the only sour note comes from the futility school of obesity care. […]
December 5, 2020 — Late on Friday, Novo Nordisk announced FDA approval for Saxenda (liraglutide 3mg) to treat obesity in teens. This marks the second such drug approved in for youth in little more than a week. Setmelanotide received approval last week for children as young as six. Make no mistake about it, we are making progress in expanding […]
November 10, 2020 — Saxenda (liraglutide) is on the brink of becoming a billion dollar drug for obesity. Yet its effectiveness in obesity is modest. On average, a person taking it might expect that their weight would go down by about eight percent. Of course, some people will have a much bigger benefit. But others will have less or […]
March 31, 2020 — While the world has been busy with COVID-19, quite a lot has been happening in obesity. Last week, JAMA Pediatrics published an important review of all the evidence-based options for treating obesity in adolescents. The bottom line? Those options are too few, but more are coming. Today, we got a good look at one of […]
February 7, 2020 — The decade just past brought quite a bit of change in drugs used to treat obesity. At the beginning of the decade, options were few. Prescribing was almost nil. Now we have five new drugs for obesity. For type 2 diabetes, weight-sparing drugs have taken a dominant role in prescribing. One of those drugs, liraglutide, […]
November 5, 2019 — Success begets success. That’s a core message we’re taking away from a late-breaking forum on emerging anti-obesity medicines. Pharmaceutical researchers reviewed an impressive range of innovations that promise to set a higher bar for effective obesity care. All of this came before ObesityWeek kicks into high gear today. Building Upon Success Mads Tang-Christensen opened the […]
June 9, 2019 — Some of the most discussed news coming from the American Diabetes Association Scientific Sessions in San Francisco is all about the PIONEER studies of oral semaglutide. This drug is presently under review at FDA for type 2 diabetes. Interest is keen because it will be the first of its class that doesn’t require an injection. […]
October 19, 2017 — This is a big week for semaglutide – a promising cousin of liraglutide. Research is ongoing to figure out just how good it will be in both type 2 diabetes and obesity. And the milestones this week were all about diabetes. But you can find some encouragement for the obesity indication, too. Unanimous Support from FDA’s […]
September 27, 2017 — Could it be that a little fine-tuning for the stomach can have a real effect on obesity? That’s the gist of the latest research on how liraglutide (Saxenda) works. The senior author on this study, Michael Camilleri, explains: Liraglutide appears to be very effective in inducing weight loss over three months of treatment. We also […]
